share_log

Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today

Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today

為什麼轉碼治療（RNAZ）股票今天交易更高
Benzinga Real-time News ·  2023/02/01 07:52
  • TransCode Therapeutics Inc (NASDAQ:RNAZ) reported preclinical proof-of-mechanism studies with its immunotherapy candidate, TTX-RIGA, in melanoma.
  • TTX-RIGA, a novel immunotherapeutic cancer candidate, is designed to work by binding to an intracellular receptor called RIG-I (retinoic acid-inducible gene I), expected to result in targeted activation of innate immunity in the tumor microenvironment.
  • In preclinical studies, TransCode's delivery of TTX-RIGA inside tumors and metastases generated an RNA-based agonist of the RIG-I gene, targeting the activation of innate immunity in the tumor microenvironment in multiple solid tumors.
  • "As with prior studies, we believe the data from this preclinical study further support the advancement of TTX-RIGA into animal studies slated to begin in February 2023," commented Zdravka Medarova, co-founder & CTO of TransCode.
  • "We believe that demonstrating successful preclinical results with TTX-RIGA is an important step in the preclinical development process and further de-risks our pipeline that includes multiple RNA approaches," added Michael Dudley, co-founder, president, and CEO of TransCode.
  • Dudley added, "we received written authorization from the FDA to proceed with our Phase 0 first-in-human (FIH) clinical trial with our lead candidate, TTX-MC138, in cancer patients with advanced solid tumors. We intend to proceed with patient enrollment as soon as possible."
  • Price Action: RNAZ shares are up 43.90% at $1.08 during the premarket session on the last check Wednesday.
  • 轉碼治療公司 （NASDAQ：RNAZ）報告了與其免疫治療候選人 TTX-RIGA 在黑色素瘤中的臨床前機制證明研究。
  • TTX-RIGA 是一種新型免疫療法候選癌症候選者，旨在通過與稱為 RIG-I（視黃酸誘導基因 I）的細胞內受體結合起作用，預計將在腫瘤微環境中對先天免疫進行靶向激活。
  • 在臨床前研究中，TranCode 在腫瘤和轉移酶內部 TTX-RIGA 的交付產生了 RIG-I 基因的 RNA 激動劑，目標是在多個實體腫瘤中的腫瘤微環境中激活先天免疫。
  • 「與之前的研究一樣，我們相信這項臨床前研究的數據進一步支持 TTX-RIGA 進入動物研究的進步，計劃於 2023 年 2 月開始，」轉碼聯合創始人兼首席技術官 Zdravka Medarova 評論道。
  • TransCode 聯合創始人、總裁兼執行長 Michael Dudley 補充道：「我們相信，與 TTX-RIGA 展示成功的臨床前結果是臨床前開發過程中的重要一步，並進一步降低我們包含多種 RNA 方法的管道風險。
  • 達德利補充道：「我們獲得 FDA 的書面授權，可以在晚期實體瘤患者中與我們的首席候選人 TTX-MC138 進行我們的 0 期首次人類（FIH）臨床試驗。我們打算盡快進行病人登記。」
  • 價格行動： RNAZ 在上次檢查週三的上市前時段期間上漲了 43.90％，價格為 1.08 美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論